{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:30:17Z","timestamp":1784759417386,"version":"3.55.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thespinejournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Spine Journal"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.spinee.2025.10.018","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:37:44Z","timestamp":1760542664000},"page":"806-820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of bone-modifying agents in preventing vertebral complications of multiple myeloma: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4458-6715","authenticated-orcid":false,"given":"Zsombor T.","family":"Gal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-0279","authenticated-orcid":false,"given":"Ethan A.","family":"Wetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian V.","family":"Nahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4849-3695","authenticated-orcid":false,"given":"Philip J.","family":"Saylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel E.","family":"Marciscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-0175","authenticated-orcid":false,"given":"Daniel G.","family":"Tobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-7491","authenticated-orcid":false,"given":"Andrew J.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5203-8619","authenticated-orcid":false,"given":"Ganesh M.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.spinee.2025.10.018_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.spinee.2025.10.018_bib0002","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","article-title":"Myeloma bone disease: pathophysiology and management","volume":"16","author":"Terpos","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.spinee.2025.10.018_bib0003","article-title":"Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: observations from real-world data","volume":"14","author":"Kim","year":"2018","journal-title":"J Bone Oncol"},{"issue":"1","key":"10.1016\/j.spinee.2025.10.018_bib0004","first-page":"11","article-title":"Effect of pathologic fractures on survival in multiple myeloma patients: a case control study","volume":"27","author":"Sonmez","year":"2008","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"2","key":"10.1016\/j.spinee.2025.10.018_bib0005","first-page":"417","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study","volume":"22","author":"Jordan","year":"2014","journal-title":"Supp Care Can Off J Multinatl Assoc Support Care Can"},{"issue":"6","key":"10.1016\/j.spinee.2025.10.018_bib0006","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1080\/13696998.2018.1457531","article-title":"Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database","volume":"21","author":"Bhowmik","year":"2018","journal-title":"J Med Econ"},{"issue":"5","key":"10.1016\/j.spinee.2025.10.018_bib0007","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3111\/13696998.2015.1132225","article-title":"Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma","volume":"19","author":"Nash Smyth","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.spinee.2025.10.018_bib0008","doi-asserted-by":"crossref","unstructured":"Tosi P. Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement. Scientifica. 2013;2013(1):104546. doi:10.1155\/2013\/104546","DOI":"10.1155\/2013\/104546"},{"issue":"1","key":"10.1016\/j.spinee.2025.10.018_bib0009","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1148\/radiology.204.1.9205246","article-title":"Vertebral compression fractures in multiple myeloma. Part I. Distribution and appearance at MR imaging","volume":"204","author":"Lecouvet","year":"1997","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.spinee.2025.10.018_bib0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00270-011-0111-4","article-title":"Percutaneous vertebroplasty in multiple myeloma: prospective long-term follow-up in 106 consecutive patients","volume":"35","author":"Anselmetti","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"11","key":"10.1016\/j.spinee.2025.10.018_bib0011","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.spinee.2020.07.004","article-title":"Identifying predictive factors for vertebral collapse fractures in multiple myeloma patients","volume":"20","author":"Zijlstra","year":"2020","journal-title":"Spine J"},{"issue":"3","key":"10.1016\/j.spinee.2025.10.018_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0187-7","article-title":"The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)","volume":"9","author":"Kyriakou","year":"2019","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.spinee.2025.10.018_bib0013","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2002.09.097","article-title":"Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma","volume":"20","author":"Dudeney","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.spinee.2025.10.018_bib0014","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3174\/ajnr.A0918","article-title":"Vertebroplasty in multiple myeloma: outcomes in a large patient series","volume":"29","author":"McDonald","year":"2008","journal-title":"Am J Neuroradiol"},{"issue":"1","key":"10.1016\/j.spinee.2025.10.018_bib0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0167-8140(96)01858-0","article-title":"Local control and survival in spinal cord compression from lymphoma and myeloma","volume":"42","author":"Wallington","year":"1997","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.spinee.2025.10.018_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103205","article-title":"Management of acute spinal cord compression in multiple myeloma","volume":"160","author":"Chen","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.spinee.2025.10.018_bib0017","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12893-017-0288-9","article-title":"Oncological and functional results of the surgical treatment of vertebral metastases in patients with multiple myeloma","volume":"17","author":"Guzik","year":"2017","journal-title":"BMC Surg"},{"key":"10.1016\/j.spinee.2025.10.018_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100999","article-title":"The use of bone-modifying agents in multiple myeloma","volume":"57","author":"Hussain","year":"2023","journal-title":"Blood Rev"},{"issue":"9","key":"10.1016\/j.spinee.2025.10.018_bib0019","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc Mayo Clin"},{"issue":"12","key":"10.1016\/j.spinee.2025.10.018_bib0020","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"2017","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.spinee.2025.10.018_bib0021","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.spinee.2025.10.018_bib0022","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.spinee.2025.10.018_bib0023","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2217\/fon-2017-0403","article-title":"Denosumab for the treatment of bone disease in solid tumors and multiple myeloma","volume":"14","author":"Yee","year":"2017","journal-title":"Future Oncol"},{"issue":"8","key":"10.1016\/j.spinee.2025.10.018_bib0024","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","article-title":"Role of bone-modifying agents in Multiple myeloma: American Society of Clinical Oncology Clinical Practice Guideline update","volume":"36","author":"Anderson","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.spinee.2025.10.018_bib0025","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.spinee.2025.10.018_bib0026","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.spinee.2025.10.018_bib0027","first-page":"390","article-title":"Modifying \u201cPico\u201d question into \u201cPicos\u201d model for more robust and reproducible presentation of the methodology employed in a scientific study","volume":"6","author":"Saaiq","year":"2017","journal-title":"World J Plast Surg"},{"key":"10.1016\/j.spinee.2025.10.018_bib0028","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.spinee.2025.10.018_bib0029","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.spinee.2025.10.018_bib0030","article-title":"R: a language and environment for statistical computing","author":"Core Team","year":"2023","journal-title":"R Foundat Statistic Comput"},{"issue":"4","key":"10.1016\/j.spinee.2025.10.018_bib0031","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.spinee.2025.10.018_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"netmeta: an R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J Stat Softw"},{"issue":"7109","key":"10.1016\/j.spinee.2025.10.018_bib0033","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.spinee.2025.10.018_bib0034","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jclinepi.2018.05.011","article-title":"GRADE guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences-inconsistency, imprecision, and other domains","volume":"111","author":"Zhang","year":"2019","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.spinee.2025.10.018_bib0035","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0221-8747(82)90013-3","article-title":"Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma","volume":"4","author":"Delmas","year":"1982","journal-title":"Metab Bone Dis Relat Res"},{"issue":"8827","key":"10.1016\/j.spinee.2025.10.018_bib0036","first-page":"1049","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Finnish Leukaemia Group Lancet Lond Engl"},{"issue":"3","key":"10.1016\/j.spinee.2025.10.018_bib0037","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF01697625","article-title":"Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications","volume":"66","author":"Clemens","year":"1993","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.spinee.2025.10.018_bib0038","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.spinee.2025.10.018_bib0039","first-page":"113","article-title":"Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy","volume":"57","author":"Kraj","year":"2000","journal-title":"Acta Pol Pharm"},{"issue":"5","key":"10.1016\/j.spinee.2025.10.018_bib0040","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1034\/j.1600-0609.2000.065005331.x","article-title":"Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma","volume":"65","author":"Terpos","year":"2000","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.spinee.2025.10.018_bib0041","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.spinee.2025.10.018_bib0042","first-page":"478","article-title":"Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience)","volume":"59","author":"Kraj","year":"2002","journal-title":"Acta Pol Pharm"},{"issue":"9","key":"10.1016\/j.spinee.2025.10.018_bib0043","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.spinee.2025.10.018_bib0044","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.spinee.2025.10.018_bib0045","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3324\/haematol.2015.128439","article-title":"Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial","volume":"100","author":"Garc\u00eda-Sanz","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.spinee.2025.10.018_bib0046","first-page":"2394","article-title":"Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases","volume":"9","author":"Ibrahim","year":"2003","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"9","key":"10.1016\/j.spinee.2025.10.018_bib0047","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (Excluding Breast and Prostate Cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.spinee.2025.10.018_bib0048","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M22-0684","article-title":"Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians","volume":"176","author":"Ayers","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.spinee.2025.10.018_bib0049","doi-asserted-by":"crossref","unstructured":"Kahwati LC, Kistler CE, Booth G, Sathe N, D'Amico Gordon R, Okah E, et al. Screening for osteoporosis to prevent fractures: an evidence review for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality (US); 2025. Accessed April 13, 2025 http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK611438\/.","DOI":"10.1001\/jama.2024.21653"},{"issue":"9","key":"10.1016\/j.spinee.2025.10.018_bib0050","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1359\/jbmr.1999.14.9.1557","article-title":"A dose-finding study of zoledronate in hypercalcemic cancer patients","volume":"14","author":"Body","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.spinee.2025.10.018_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2010.06.001","article-title":"The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis","volume":"40","author":"Jansen","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"18","key":"10.1016\/j.spinee.2025.10.018_bib0052","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.spinee.2025.10.018_bib0053","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.spinee.2025.10.018_bib0054","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000226539","article-title":"Multiple myeloma presenting with spinal cord compression","volume":"45","author":"Spiess","year":"2009","journal-title":"Oncology"},{"issue":"17","key":"10.1016\/j.spinee.2025.10.018_bib0055","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","article-title":"Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution","volume":"158","author":"Blad\u00e9","year":"1998","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.spinee.2025.10.018_bib0056","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3324\/haematol.2017.185264","article-title":"Denosumab for bone lesions in multiple myeloma \u2013 what is its value?","volume":"103","author":"Goldstein","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.spinee.2025.10.018_bib0057","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10518","article-title":"The role of bone-modifying agents in myeloma bone disease","volume":"5","author":"Lu","year":"2021","journal-title":"JBMR Plus"},{"issue":"3","key":"10.1016\/j.spinee.2025.10.018_bib0058","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/ejh.13003","article-title":"A historical perspective on milestones in multiple myeloma research","volume":"100","author":"Ribatti","year":"2018","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.spinee.2025.10.018_bib0059","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: the (r) evolution of current therapy and a glance into the future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.spinee.2025.10.018_bib0060","first-page":"44","article-title":"Diagnosis and management of vertebral compression fractures","volume":"94","author":"McCarthy","year":"2016","journal-title":"Am Fam Physician"},{"issue":"4","key":"10.1016\/j.spinee.2025.10.018_bib0061","doi-asserted-by":"crossref","first-page":"46","DOI":"10.7812\/TPP\/12-037","article-title":"Evaluation and management of vertebral compression fractures","volume":"16","author":"Alexandru","year":"2012","journal-title":"Perm J"},{"key":"10.1016\/j.spinee.2025.10.018_bib0062","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00003086-198410000-00016","article-title":"Burst fractures of the thoracic and lumbar spine","volume":"189","author":"DeWald","year":"1984","journal-title":"Clin Orthop"}],"container-title":["The Spine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1529943025008502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1529943025008502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:17:28Z","timestamp":1774023448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1529943025008502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1529943025008502"],"URL":"https:\/\/doi.org\/10.1016\/j.spinee.2025.10.018","relation":{},"ISSN":["1529-9430"],"issn-type":[{"value":"1529-9430","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of bone-modifying agents in preventing vertebral complications of multiple myeloma: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"The Spine Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.spinee.2025.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}